Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Medical Genetics · Hereditary Transthyretin Amyloidosis

When Should Family Members Get hATTR Genetic Testing?

At a Glance

Adult first-degree relatives of someone with a known disease-causing TTR variant should usually be offered targeted genetic testing through a genetic counselor at age 18 or older. Testing younger children is generally reserved for symptoms or a rare early-onset variant.

Receiving a diagnosis of hereditary ATTR (hATTR) amyloidosis naturally brings up immediate concerns for your children and other relatives. Because hATTR amyloidosis is passed down in an autosomal dominant pattern—meaning each biological child of a person with a disease-causing mutation has a 50% chance of inheriting it—informing your family is an important step [1]. However, testing is generally reserved for adults. Medical guidelines recommend deferring predictive genetic testing for minors until they are at least 18 years old [2]. For adult relatives, testing should be done systematically through a process called cascade testing, but only after comprehensive discussion with a genetic counselor [1][2].

Testing Minors: Why We Usually Wait

Because hATTR amyloidosis is predominantly an adult-onset disease, children usually do not develop symptoms during childhood. Therefore, expert consensus guidelines generally recommend waiting until an at-risk individual is at least 18 years old to offer predictive genetic testing [2].

Deferring the test allows children to grow up without the psychological burden of carrying a genetic risk they cannot act upon during youth [3][2]. More importantly, waiting preserves their right to make their own informed choice as an adult.

Note: There are rare exceptions. If a child develops symptoms that could be related to amyloidosis, or if your family has a very rare, early-onset TTR variant (the specific mutation), they should undergo a diagnostic evaluation by a specialist regardless of age [1].

Cascade Testing for Adult Relatives

For adults in your family, the recommended approach is cascade testing [4]. This means offering targeted testing for your specific known familial variant to your closest biological relatives first—such as your parents, siblings, and adult children. If a relative tests positive, testing is then offered to their first-degree relatives [4]. (Spouses or partners do not need testing unless they have their own family history of the disease).

Testing should look specifically for the pathogenic (disease-causing) mutation already identified in your family. A relative who tests negative for this specific variant generally does not have the familial risk and does not require hATTR surveillance [1].

If an adult relative tests positive, they are considered to have an inherited genetic risk. It is crucial to understand that having the genetic mutation does not mean they have the disease, nor does it guarantee they will ever develop it [1][5]. The disease has variable penetrance (the likelihood of showing symptoms) and the age of onset can range widely depending on the specific TTR variant and individual factors [1][6][7].

A positive result means the relative should begin an individualized schedule of clinical monitoring (such as neurologic, cardiac, and autonomic assessments) tailored to the predicted age of onset for that specific variant [8][9][6]. This surveillance aims to catch any early signs of clinical disease so that doctors can evaluate them for disease-modifying therapies at the right time [4][10].

The Crucial Role of Genetic Counselors

At-risk family members should not rely on direct-to-consumer commercial DNA tests [2]. Instead, testing should be coordinated through a genetic counselor or a multidisciplinary amyloidosis center [1]. A genetic counselor will help your relatives navigate two major non-medical considerations before they decide to get tested:

  • Insurance Considerations (U.S.): In the United States, a federal law called the Genetic Information Nondiscrimination Act (GINA) protects against genetic discrimination in health insurance and employment [11][12]. However, GINA does not cover life, disability, or long-term care insurance [11][12]. While some states offer additional protections, genetic counselors often discuss the importance of securing these insurance policies before a positive genetic test enters a person’s medical record [13]. This is a personal decision and should not delay urgent medical care for anyone experiencing symptoms.
  • Emotional and Psychological Impact: Learning you are predisposed to a serious condition can cause significant anxiety and fear [3][10]. A genetic counselor provides a period of reflection before the test and ensures that psychosocial support is in place to help the individual handle whatever the results may show [2].

Common questions in this guide

At what age should relatives be tested for hereditary ATTR amyloidosis?
Predictive genetic testing is generally offered to at-risk relatives when they are adults, usually at age 18 or older. Because hereditary ATTR amyloidosis usually begins in adulthood, waiting allows the person to make an informed choice about testing. Earlier diagnostic evaluation may be appropriate if a child has concerning symptoms or the family has a rare early-onset TTR variant.
Which family members should have cascade testing for hATTR?
Testing usually starts with adult first-degree biological relatives, including parents, siblings, and children, using the specific disease-causing TTR variant identified in the family. If one of them tests positive, testing can be offered to that person’s first-degree relatives. Spouses and partners generally do not need testing unless they have their own family history of the condition.
What does a positive hATTR genetic test mean?
A positive result means the person inherited the familial TTR variant and has an increased genetic risk for hereditary ATTR amyloidosis; it does not prove that disease is present or guarantee that symptoms will develop. The likelihood of symptoms and their age of onset vary by variant and individual. A genetic counselor and specialist can create a monitoring plan based on that risk.
What does a negative test for the family’s TTR variant mean?
A negative result for the specific disease-causing TTR variant known in the family generally means the relative did not inherit that familial risk. They usually do not need hereditary ATTR surveillance based on that variant. The result should still be interpreted with a genetic counselor or other qualified clinician.
Why should genetic counseling happen before hATTR testing?
A genetic counselor can confirm the correct familial variant, explain what positive and negative results mean, and discuss emotional effects before testing. In the United States, a counselor can also review that GINA protects health insurance and employment but does not cover life, disability, or long-term-care insurance. Direct-to-consumer DNA tests are not a substitute for clinical testing.
What monitoring is needed if an adult relative tests positive?
A person with a positive familial TTR test should receive individualized clinical monitoring even if they have no symptoms. Follow-up may include neurologic, cardiac, and autonomic assessments, with timing based on the specific variant and its expected age of onset. Monitoring helps clinicians recognize early disease and consider disease-modifying treatment when appropriate.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific name of my pathogenic TTR variant, and what is its typical age of onset and phenotype?
  2. 2.Can you provide a standardized 'family letter' that explains the genetic risk and testing process, which I can share with my relatives?
  3. 3.Can you refer my adult family members to a genetic counselor who specializes in amyloidosis?
  4. 4.If an adult relative tests positive for the variant but has no symptoms, what individualized monitoring schedule would they need?
  5. 5.How does a negative result for my specific mutation change a family member's need for future screening?

References

References (13)
  1. 1

    Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.

    Gillmore JD, Reilly MM, Coats CJ, et al.

    Advances in therapy 2022; (39(6)):2292-2301 doi:10.1007/s12325-022-02139-9.

    PMID: 35419651
  2. 2

    Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus.

    Grandis M, Obici L, Luigetti M, et al.

    Orphanet journal of rare diseases 2020; (15(1)):348 doi:10.1186/s13023-020-01633-z.

    PMID: 33317601
  3. 3

    Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden.

    González-Moreno J, Gaya-Barroso A, Losada-López I, et al.

    Orphanet journal of rare diseases 2021; (16(1)):266 doi:10.1186/s13023-021-01910-5.

    PMID: 34112225
  4. 4

    Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: Two years of experience in a neurological clinic.

    Di Stefano V, Lupica A, Alonge P, et al.

    European journal of neurology 2024; (31(1)):e16065 doi:10.1111/ene.16065.

    PMID: 37725003
  5. 5

    Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review.

    Merino-Merino AM, Labrador-Gomez J, Sanchez-Corral E, et al.

    Biomedicines 2023; (12(1)) doi:10.3390/biomedicines12010025.

    PMID: 38275387
  6. 6

    Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.

    Conceição I, Damy T, Romero M, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(1)):3-9 doi:10.1080/13506129.2018.1556156.

    PMID: 30793974
  7. 7

    Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.

    Dispenzieri A, Coelho T, Conceição I, et al.

    Orphanet journal of rare diseases 2022; (17(1)):236 doi:10.1186/s13023-022-02359-w.

    PMID: 35717381
  8. 8

    Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies.

    Ueda M, Sekijima Y, Koike H, et al.

    Journal of the neurological sciences 2020; (414()):116813 doi:10.1016/j.jns.2020.116813.

    PMID: 32353608
  9. 9

    Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.

    Adams D, Algalarrondo V, Polydefkis M, et al.

    Orphanet journal of rare diseases 2021; (16(1)):411 doi:10.1186/s13023-021-01960-9.

    PMID: 34602081
  10. 10

    Genetic counselling for at-risk family members with hereditary transthyretin amyloidosis: data from a single-centre study.

    Nakamura K, Yoshinaga T, Sakyu A, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(3)):179-183 doi:10.1080/13506129.2024.2357094.

    PMID: 38795075
  11. 11

    The persistent lack of knowledge and misunderstanding of the Genetic Information Nondiscrimination Act (GINA) more than a decade after passage.

    Lenartz A, Scherer AM, Uhlmann WR, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(12)):2324-2334 doi:10.1038/s41436-021-01268-w.

    PMID: 34400812
  12. 12

    GINA at 10 years: the battle over 'genetic information' continues in court.

    Suter SM

    Journal of law and the biosciences 2018; (5(3)):495-526 doi:10.1093/jlb/lsz002.

    PMID: 31143453
  13. 13

    Can Genetic Nondiscrimination Laws Save Lives?

    Rothstein MA

    The Hastings Center report 2021; (51(1)):6-7 doi:10.1002/hast.1204.

    PMID: 33315242

This page explains family genetic testing for hereditary ATTR amyloidosis for informational purposes only and does not constitute medical advice. A genetic counselor or amyloidosis specialist can advise you about your family’s situation.